PRTA Stock Analysis
PR
Uncovered
Prothena Corporation PLC is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Prothena Corp. Plc is a clinical-stage neuroscience company. The firm is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The firm is also advancing several discovery and preclinical-stage programs for neurological diseases with unmet medical needs such as AD and amyotrophic lateral sclerosis (ALS). The firm's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis. The firm's pipeline includes AL Amyloidosis & Birtamimab, Parkinson’s Disease & Prasinezumab, Transthyretin amyloidosis (ATTR) & PRX004, Alzheimer’s Disease and Pioneering Neuroscience.